We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medical Product's Q4 Earnings on Feb 24: VWR, SARTF, HMSY
Read MoreHide Full Article
With 411 S&P members’ (88.4% of the index’s total market cap) results already out, the fourth-quarter earnings season is almost at the finishing line. According to our latest Earnings Preview, the scorecard so far has portrayed an encouraging picture with the quarter emerging as the highest with respect to earnings growth over the past two years.
Till Feb 17, total earnings for these members have gone up 8% on 4.9% higher revenues with 68.9% beating earnings estimates and 54.7% exceeding revenue expectations.
Per the preview report, Medical is one of the 13 broader sectors among the 16 Zacks sectors which have so far reported earnings growth. Among the 83.3% members of this sector who have made their quarterly releases, earnings and revenue beat are standing at impressive levels of 80% and 53.3%, respectively. The sector has delivered 4.8% earnings growth on the back of 5.3% higher revenues in the quarter.
What’s in Store for the Med-Product Space?
Medical Product, an important part within the broader Medical sector, holds a lot of promise at this moment. We note that the republican win has ensured a great victory for the entire industry as the likely revocation of the 2.3% medical device excise tax is going to be a big bonus for both the behemoths and small players.
According to the MedTech community, the cancellation of this tax along with other taxes will directly address issues like lack of opportunity for research and development, innovation, pipeline development, and make investments needed to accelerate patient and provider access to innovative health care products. This will also help in boosting job creation and quality of patient care, offering companies in the space an opportunity to strengthen their position to cope with the new situation.
Let’s take a look at the major Medical Product stocks slated to release their fourth-quarter 2016 numbers on Feb 24:
VWR Corporation
Headquartered in Radnor, PA, VWR Corporation is an independent worldwide provider of products, services and solutions to laboratory and production facilities. The company is currently facing several issues including margin pressure, strengthening of domestic currency and competitive landscape. However, upside may come from several recent acquisitions and international growth.
Our proven model does not conclusively show that VWR is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. You can see the complete list of today’s Zacks #1 Rank stocks here.
VWR currently holds a Zacks Rank #4 (Sell) and has an Earnings ESP of -2.27%. That is because the Most Accurate estimate stands at 43 cents while the Zacks Consensus Estimate is pegged higher at 44 cents.
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services.
While a Zacks Rank #3 increases increase the predictive power of the ESP, a 0.00% ESP makes a surprise prediction uncertain. Both the Most Accurate estimate and the Zacks Consensus Estimate stand at 49 cents. We note that, in the last reported quarter, the company registered an earnings miss of 38.89%.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
HMS Holdings Corp.
This is a provider of coordination of benefits, payment integrity and care management solutions for payers. The company serves State Medicaid programs, commercial health plans, federal government health agencies and other healthcare payers and sponsors.
The stock’s Zacks Rank #4 along with a 0.00% ESP also makes surprise prediction uncertain. Both the Most Accurate estimate and the Zacks Consensus Estimate stand at 16 cents. In the last reported quarter, the company registered an earnings beat of 57.14% and the trailing 12-month average surprise was a positive 25.88%.
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Medical Product's Q4 Earnings on Feb 24: VWR, SARTF, HMSY
With 411 S&P members’ (88.4% of the index’s total market cap) results already out, the fourth-quarter earnings season is almost at the finishing line. According to our latest Earnings Preview, the scorecard so far has portrayed an encouraging picture with the quarter emerging as the highest with respect to earnings growth over the past two years.
Till Feb 17, total earnings for these members have gone up 8% on 4.9% higher revenues with 68.9% beating earnings estimates and 54.7% exceeding revenue expectations.
Per the preview report, Medical is one of the 13 broader sectors among the 16 Zacks sectors which have so far reported earnings growth. Among the 83.3% members of this sector who have made their quarterly releases, earnings and revenue beat are standing at impressive levels of 80% and 53.3%, respectively. The sector has delivered 4.8% earnings growth on the back of 5.3% higher revenues in the quarter.
What’s in Store for the Med-Product Space?
Medical Product, an important part within the broader Medical sector, holds a lot of promise at this moment. We note that the republican win has ensured a great victory for the entire industry as the likely revocation of the 2.3% medical device excise tax is going to be a big bonus for both the behemoths and small players.
According to the MedTech community, the cancellation of this tax along with other taxes will directly address issues like lack of opportunity for research and development, innovation, pipeline development, and make investments needed to accelerate patient and provider access to innovative health care products. This will also help in boosting job creation and quality of patient care, offering companies in the space an opportunity to strengthen their position to cope with the new situation.
Let’s take a look at the major Medical Product stocks slated to release their fourth-quarter 2016 numbers on Feb 24:
VWR Corporation
Headquartered in Radnor, PA, VWR Corporation is an independent worldwide provider of products, services and solutions to laboratory and production facilities. The company is currently facing several issues including margin pressure, strengthening of domestic currency and competitive landscape. However, upside may come from several recent acquisitions and international growth.
Our proven model does not conclusively show that VWR is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. You can see the complete list of today’s Zacks #1 Rank stocks here.
VWR currently holds a Zacks Rank #4 (Sell) and has an Earnings ESP of -2.27%. That is because the Most Accurate estimate stands at 43 cents while the Zacks Consensus Estimate is pegged higher at 44 cents.
VWR Corporation Price and EPS Surprise
VWR Corporation Price and EPS Surprise | VWR Corporation Quote
Sartorius AG (SARTF - Free Report)
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services.
While a Zacks Rank #3 increases increase the predictive power of the ESP, a 0.00% ESP makes a surprise prediction uncertain. Both the Most Accurate estimate and the Zacks Consensus Estimate stand at 49 cents. We note that, in the last reported quarter, the company registered an earnings miss of 38.89%.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
HMS Holdings Corp.
This is a provider of coordination of benefits, payment integrity and care management solutions for payers. The company serves State Medicaid programs, commercial health plans, federal government health agencies and other healthcare payers and sponsors.
The stock’s Zacks Rank #4 along with a 0.00% ESP also makes surprise prediction uncertain. Both the Most Accurate estimate and the Zacks Consensus Estimate stand at 16 cents. In the last reported quarter, the company registered an earnings beat of 57.14% and the trailing 12-month average surprise was a positive 25.88%.
HMS Holdings Corp Price and EPS Surprise
HMS Holdings Corp Price and EPS Surprise | HMS Holdings Corp Quote
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>